patient subgroup...
non invasive oxygen
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
anti-inflammatory therapies - versus potential COVID-19 treatments - for COVID 19 hospitalized
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 death D28 0.99 [0.94, 1.06]< 1 3% 8 studies (8/-) 56.7 % some concern serious moderate crucial - death or transfer to ICU 0.83 [0.35, 1.95]< 1 0% 1 study (1/-) 66.5 % NA not evaluable crucial - deaths 0.99 [0.94, 1.05]< 1 0% 12 studies (12/-) 57.1 % some concern critical moderate crucial - deaths (time to event analysis only) 0.42 [0.06, 2.87]< 1 72% 2 studies (2/-) 81.1 % some concern not evaluable moderate crucial - clinical deterioration 0.18 [0.05, 0.57]< 1 14% 4 studies (4/-) 99.8 % some concern not evaluable moderate important - clinical improvement 10.27 [1.17, 90.18]> 1 0% 1 study (1/-) 98.2 % NA not evaluable important - clinical improvement (14-day) 10.27 [1.17, 90.18]> 1 0% 1 study (1/-) 98.2 % NA not evaluable important - clinical improvement (28-day) 3.68 [0.18, 75.54]> 1 0% 1 study (1/-) 79.8 % NA not evaluable important - clinical improvement (7-day) 6.72 [1.50, 30.07]> 1 0% 1 study (1/-) 99.4 % NA not evaluable important - death or ventilation 0.94 [0.78, 1.15]< 1 70% 2 studies (2/-) 71.9 % some concern not evaluable moderate important - hospital discharge 0.98 [0.94, 1.03]> 1 0% 2 studies (2/-) 21.5 % some concern not evaluable moderate important - mechanical ventilation 0.94 [0.76, 1.15]< 1 34% 5 studies (5/-) 73.1 % some concern serious moderate important - radiologic improvement (14-day) 2.87 [1.56, 5.28]> 1 0% 1 study (1/-) 100.0 % NA not evaluable important - viral clearance 1.71 [0.80, 3.64]> 1 0% 1 study (1/-) 91.7 % NA not evaluable important - viral clearance by day 7 1.71 [0.80, 3.64]> 1 0% 1 study (1/-) 91.7 % NA not evaluable important - ICU admission 0.93 [0.55, 1.57]< 1 0% 3 studies (3/-) 61.1 % some concern not evaluable moderate non important - recovery 3.46 [1.05, 11.35]> 1 0% 1 study (1/-) 97.9 % NA not evaluable non important - safety endpoints 00 serious adverse events 0.19 [0.04, 0.84]< 1 0% 3 studies (3/-) 98.6 % some concern not evaluable moderate important - adverse events 1.24 [0.77, 2.00]< 1 0% 6 studies (6/-) 19.2 % low not evaluable high non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.